Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immunomedics Inc (IMMU)

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,308,312
  • Shares Outstanding, K 231,144
  • Annual Sales, $ 300 K
  • Annual Income, $ -357,190 K
  • 60-Month Beta 2.90
  • Price/Sales 68,810.40
  • Price/Cash Flow N/A
  • Price/Book 34.29
Trade IMMU with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.73
  • Most Recent Earnings -0.30 on 08/05/20
  • Next Earnings Date 11/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.33
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +48.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.84 +3.56%
on 09/30/20
87.93 -0.08%
on 10/22/20
+2.81 (+3.30%)
since 09/22/20
3-Month
37.85 +132.13%
on 09/04/20
87.93 -0.08%
on 10/22/20
+44.70 (+103.57%)
since 07/22/20
52-Week
8.80 +898.41%
on 04/03/20
87.93 -0.08%
on 10/22/20
+71.77 (+446.05%)
since 10/22/19

Most Recent Stories

More News
Portnoy Law Firm: Tactile Systems Technology, Inc., Pintec Technologies Holdings Limited, and Immunomedics, Inc. Investors Have Limited Amount of Time Before Class Action Deadline

Investors with losses are encouraged to contact Attorney Lesley F. Portnoy.

TCMD : 10.46 (-6.36%)
PT : 1.6000 (-5.88%)
IMMU : 87.86 (+0.05%)
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam

Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with a high unmet medical need, today announced...

PCSA : 1.9900 (+5.29%)
FENC : 5.80 (-2.65%)
IMMU : 87.86 (+0.05%)
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...

PCSA : 1.9900 (+5.29%)
FENC : 5.80 (-2.65%)
IMMU : 87.86 (+0.05%)
Gilead Sciences Completes Acquisition of Immunomedics, Inc.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate.

GILD : 63.67 (+0.78%)
IMMU : 87.86 (+0.05%)
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma

MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...

IMMU : 87.86 (+0.05%)
Moore Kuehn Encourages IMMU, MOBL, MR, and SCBH Investors to Contact Law Firm

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...

IMMU : 87.86 (+0.05%)
MOBL : 7.04 (unch)
SCBH : 17.2500 (+1.47%)
MR : 5.36 (-1.29%)
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, RST, IMMU, VAR

NEW YORK, NY / ACCESSWIRE / September 26, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of...

GILD : 63.67 (+0.78%)
CBMG : 19.75 (unch)
RST : 29.99 (unch)
IMMU : 87.86 (+0.05%)
VAR : 177.07 (-0.02%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IMMU, VRTU, RST, and CBMG Buyouts

WILMINGTON, Del., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

IMMU : 87.86 (+0.05%)
VRTU : 51.33 (+0.03%)
RST : 29.99 (unch)
CBMG : 19.75 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, AKCA, VRTU, IMMU

NEW YORK, NY / ACCESSWIRE / September 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of...

GILD : 63.67 (+0.78%)
CBMG : 19.75 (unch)
AKCA : 18.17 (+0.17%)
VRTU : 51.33 (+0.03%)
IMMU : 87.86 (+0.05%)
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer

Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)

IMMU : 87.86 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 88.13
1st Resistance Point 88.00
Last Price 87.86
1st Support Level 87.66
2nd Support Level 87.45
3rd Support Level N/A

See More

52-Week High 87.93
Last Price 87.86
Fibonacci 61.8% 57.70
Fibonacci 50% 48.37
Fibonacci 38.2% 39.03
52-Week Low 8.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar